Post
of 161,689
Here’s some good links
Safety & Efficacy of Long-Acting Injectables for HIV-1 (CAB‑LA & RPV‑LA)
— Shows LA-ARVs are safe, effective, and likely to improve adherence for prevention and treatment 
2. IAVI Report on LA Injectable PrEP
— Demonstrates successful prevention in cisgender women using cabotegravir every 8 weeks 
3. Clinical Trial Summary (UAB LATITUDE Study)
— Confirms injectable ARVs outperform oral therapy for patients struggling with adherence  
4. Review of Synthetic Receptor Systems (CAR, synNotch)
— Reflects the broader field of conditional biologic activation—context-aware, programmable delivery 
5. Review on Activatable Antibodies & Mimetics
— Highlights ongoing development of biologics that engage only under specific conditions 
Safety & Efficacy of Long-Acting Injectables for HIV-1 (CAB‑LA & RPV‑LA)
— Shows LA-ARVs are safe, effective, and likely to improve adherence for prevention and treatment 
2. IAVI Report on LA Injectable PrEP
— Demonstrates successful prevention in cisgender women using cabotegravir every 8 weeks 
3. Clinical Trial Summary (UAB LATITUDE Study)
— Confirms injectable ARVs outperform oral therapy for patients struggling with adherence  
4. Review of Synthetic Receptor Systems (CAR, synNotch)
— Reflects the broader field of conditional biologic activation—context-aware, programmable delivery 
5. Review on Activatable Antibodies & Mimetics
— Highlights ongoing development of biologics that engage only under specific conditions